STOCK TITAN
  1. Home
  2. News
  3. AMGN

AMGEN Inc. - AMGN STOCK NEWS

Welcome to our dedicated news page for AMGEN (Ticker: AMGN), a resource for investors and traders seeking the latest updates and insights on AMGEN.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect AMGEN's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of AMGEN's position in the market.

News
AMGEN PRESENTS NEW CARDIOVASCULAR RESEARCH AT AHA 2023
Rhea-AI Summary
Amgen (NASDAQ:AMGN) announced new data reinforcing the safety and efficacy of Repatha (evolocumab) from the FOURIER Open Label Extension (OLE) trial. The data showed no cognitive decline associated with very low levels of LDL-C. Amgen also presented new research from the Phase 2 OCEAN(a)-DOSE study of its investigational small interfering RNA (siRNA) olpasiran, focusing on cardiovascular risks associated with elevated Lp(a).
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.23%
Tags
none
-
News
AMGEN PRESENTS NEW RESEARCH IN EARLY PSORIATIC ARTHRITIS AT ACR 2023
Rhea-AI Summary
AMGN: Otezla Improves Disease Control in Psoriatic Arthritis Patients - Amgen's Otezla (apremilast) shows promising results in a Phase 4 study for early oligoarticular psoriatic arthritis, with twice as many patients achieving minimal disease activity compared to placebo.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.79%
Tags
none
-
News
AMGEN PRESENTS NEW DATA FROM PHASE 2 TRIAL OF DAZODALIBEP IN SJÖGREN'S SYNDROME AT ACR 2023
Rhea-AI Summary
Amgen (NASDAQ:AMGN) Announces Positive Results from Phase 2 Trial of Dazodalibep for Sjögren's Treatment at ACR Convergence 2023
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.79%
Tags
clinical trial
News
Epidemiology and Genetics of Clonal Hematopoiesis, a Premalignant Hematopoietic Stem Cell Condition
Rhea-AI Summary
A new study from deCODE genetics, a subsidiary of Amgen, provides insights into clonal hematopoiesis. The study used whole-genome sequence data from over 176,000 people and found that clonal hematopoiesis is very common in the elderly, approaching 50% in people over 80 years old. Smoking was found to accelerate the development of clonal hematopoiesis. The study also identified mutations that drive clonal expansion and 25 inherited sequence variants that predispose individuals to develop clonal hematopoiesis.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.1%
Tags
none
-
News
AMGEN PRESENTS NEW DATA THAT SHOW BLOOD PRESSURE DECREASES FOR ADULTS TREATED WITH KRYSTEXXA® (PEGLOTICASE)
Rhea-AI Summary
Amgen announces new data for KRYSTEXXA showing a decrease in blood pressure during treatment of adults with chronic gout refractory to oral urate-lowering treatment. The data will be presented at the American Society of Nephrology Kidney Week.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.2%
Tags
none
-
News
AMGEN TO PRESENT DATA AT ACR 2023 ACROSS EXPANDED RHEUMATOLOGY PIPELINE AND PORTFOLIO
Rhea-AI Summary
Amgen announces the presentation of new scientific and clinical research in rheumatology at the American College of Rheumatology Convergence 2023. The data includes studies on Sjögren's Syndrome, uncontrolled gout, severe active ANCA-associated vasculitis, and psoriatic arthritis.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.01%
Tags
conferences
News
AMGEN REPORTS THIRD QUARTER FINANCIAL RESULTS
Rhea-AI Summary
Amgen (NASDAQ:AMGN) has released its financial results for the third quarter of 2023. The company reported positive earnings and revenue growth compared to the same period last year. Amgen's strong performance was driven by increased sales of its key drugs, including Enbrel and Prolia. The company also announced progress in its pipeline, with several promising drug candidates in late-stage development.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.85%
Tags
earnings
-
News
A large international study of migraine reveals new biological pathways for treatment
Rhea-AI Summary
A large international study led by deCODE Genetics reveals new biological pathways for migraine treatment. The study analyzed genetic data from over 1.3 million participants and identified 44 variants associated with migraine, including 12 novel variants. The findings provide insights into the genetics and biology of migraine and could lead to the development of novel drug targets.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.9%
Tags
none
-
News
AMGEN ANNOUNCES WEBCAST OF 2023 THIRD QUARTER FINANCIAL RESULTS
Rhea-AI Summary
Amgen (NASDAQ:AMGN) will report its Q3 financial results on October 31, 2023, followed by a conference call with the investment community. The webcast will be available on Amgen's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.9%
Tags
earnings
News
AMGEN ANNOUNCES 2023 FOURTH QUARTER DIVIDEND
Rhea-AI Summary
Amgen declares $2.13 per share dividend for Q4 2023
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.43%
Tags
dividends
Stock AMGN logo
AMGEN Inc.

Nasdaq:AMGN

AMGN Rankings

#73 Ranked by Market Cap
#2185 Ranked by Stock Gains
#1040 Ranked by Dividends

AMGN Stock Data

142.36B
534.35M
0.25%
80.73%
1.95%
Biological Product (except Diagnostic) Manufacturing
Manufacturing
Link
US
Thousand Oaks

About AMGN

Amgen Inc. is an American multinational biopharmaceutical company headquartered in Thousand Oaks, California. One of the worlds largest independent biotechnology companies, Amgen was established in Thousand Oaks, California, in 1980.